Pneumonia Vaccine

Vaccine Safe But Ineffective in the Middle-Aged and Elderly

Published in TB and Outbreaks Week, March 2nd, 1998

Until now, the protective effectiveness of immunization against pneumonia by the 23-valent pneumococcal capsular polysaccharide vaccine in the middle-aged and elderly has not been clear.

Now, in a study in The Lancet, a research team from Sweden has reported that this vaccine was not effective for patients in this age group (Lancet, February 7, 1998;350:399-403).

Dr. Ake Ortqvist and colleagues from various centers in Sweden enrolled into their study 691 patients aged 50-85 years who had been in-patients for community-acquired pneumonia. Apart from the bout of pneumonia they were treated for, the patients were not otherwise immunologically...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (1998-03-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry